These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 25068470)

  • 21. Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.
    Rajan SS; Lyman GH; Carpenter WR; Stearns SC
    Breast Cancer Res Treat; 2011 Jun; 127(2):511-20. PubMed ID: 20976544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy.
    Lai Y; Palazzo JP; Cristofanilli M; Hyslop T; Civan J; Avery T; Myers RE; Li B; Ye Z; Xing J; Yang H
    Breast Cancer Res Treat; 2014 Nov; 148(1):175-85. PubMed ID: 25261294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
    J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic growth factors in myelodysplastic syndromes.
    Steensma DP
    Semin Oncol; 2011 Oct; 38(5):635-47. PubMed ID: 21943670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer.
    Schroeder MC; Tien YY; Wright K; Halfdanarson TR; Abu-Hejleh T; Brooks JM
    Lung Cancer; 2016 May; 95():28-34. PubMed ID: 27040848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
    Ramsey SD; Howlader N; Etzioni RD; Donato B
    J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
    Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
    Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
    Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
    Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer.
    Hayman JA; Abrahamse PH; Lakhani I; Earle CC; Katz SJ
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1001-7. PubMed ID: 17689029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic growth factors in lung cancer.
    Genova C; Rijavec E; Grossi F
    Curr Opin Oncol; 2016 Mar; 28(2):135-44. PubMed ID: 26742020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study.
    Kadakia A; Rajan SS; Abughosh S; Du XL; Johnson ML
    Am J Clin Oncol; 2015 Apr; 38(2):165-73. PubMed ID: 23608830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.
    Kreys ED; Kim TY; Delgado A; Koeller JM
    J Oncol Pract; 2014 May; 10(3):168-73. PubMed ID: 24839275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
    Seetasith A; Holdford D; Shah A; Patterson J
    Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance.
    Warren JL; Butler EN; Stevens J; Lathan CS; Noone AM; Ward KC; Harlan LC
    J Clin Oncol; 2015 Feb; 33(4):312-8. PubMed ID: 25534387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.